Stevenage bioscience hub
Located amid a cluster of academic centres of excellence and other pharma companies, the Stevenage Bioscience Catalyst campus is a major hub for early-stage biotechnology companies.
It provides small to medium-sized biotech and life sciences companies and start-ups with access to the expertise, networks and scientific facilities traditionally associated with multinational pharmaceutical companies.
A key aim of Stevenage Bioscience Catalyst is to pioneer a culture of open-innovation that will place the UK bioscience sector at the forefront of worldwide biomedical discovery and deliver cutting edge healthcare solutions.
The Stevenage campus is the result of a unique partnership between GSK, the Department of Business, Innovation & Skills, the Wellcome Trust, the East of England Development Agency and the Technology Strategy Board. GSK provided land, facilities and investment totalling almost £11m to help build and launch the campus.
The campus opened for business on 9 February 2012 and welcomed its first tenant – Aptiv Solutions – on the same day.
Facilities and opportunities
With long-term plans to expand the campus fivefold, the Stevenage Bioscience Catalyst campus offers a range of equipment and commercial opportunities that would be impossible for a small or medium-sized enterprise (SME) to develop alone.
In addition to its outstanding scientific facilities, Stevenage Bioscience Catalyst also offers valuable opportunities for scientific and commercial networking. Tenants retain full independence and the freedom to interact with any commercial partners.
More open innovation
Diseases of the developing world
To achieve sustainable improvements in access to essential care and medicines in the developing world, we need to have a dedicated strategy devoted to it
Non-communicable diseases in Africa
A collaborative approach to helping us to better understand non-communicable diseases (NCDs) in Africa
Targeting the immune system through open innovation
We have at least 10 research units focused on immunology across several therapeutic areas and have multiple research programmes underway
We know that we need to partner with other companies, academic institutions and research charities to discover more